Centene (CNC) stock is undervalued, now that the company has laid out building blocks on how to operate if enhanced affordable care act, or ACA, exchange subsidies expire after 2025, UBS said Friday.
Centene expects a 30% drop in ACA exchange enrollment from 2025, creating a $1 earnings per share headwind for 2026, UBS said in the note, which is conservative compared to its peers. However, the brokerage expects the enrollment decline to be offset partially by 15% per-member-per-month, or PMPM, growth.
The firm also expects Medicaid medical loss ratio to improve in 2026 and Medicare to achieve breakeven by 2027.
"We continue to believe Medicaid rates will improve as states are mandated to pay actuarially sound rates," UBS said. "The rate update for 2025 would suggest states are taking notice and further benefits from repricing will annualize into 2026 as well."
The firm upgraded Centene to buy from neutral with a raised price target to $80.
Centene shares were up more than 3% in recent trading.
Price: 60.03, Change: +2.03, Percent Change: +3.50
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。